- Valspodar
-
- $987.00
-
2026-07-27
- CAS:121584-18-7
- Purity: 98.00%
- Supply Ability: 10g
- Valspodar
-
- $15.00
-
2021-07-13
- CAS:121584-18-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
- Valspodar
-
- $15.00
-
2021-07-10
- CAS:121584-18-7
- Min. Order: 1KG
- Purity: 99%+ HPLC
|
| | Valspodar Basic information |
| Product Name: | Valspodar | | Synonyms: | Valspodar;3'-Keto-bmt(1)-Val(2)-cyclosporin a;Cyclosporin A, 6-((R-(E))-6,7-didehydro-N,4-dimethyl-3-oxo-L-2-aminooctanoic acid)-7-L-valine-;Psc 833;Sdz psc 833;Sdz-psc-833;Cyclo[[(2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl]-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl];6-[(2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoicacid]-7-L-valine-cyclosporinA | | CAS: | 121584-18-7 | | MF: | C63H111N11O12 | | MW: | 1214.62 | | EINECS: | 1312995-182-4 | | Product Categories: | Intermediates & Fine Chemicals;Peptides;Pharmaceuticals | | Mol File: | 121584-18-7.mol |  |
| | Valspodar Chemical Properties |
| Melting point | 143-145°C | | Boiling point | 1290.1±65.0 °C(Predicted) | | alpha | D20 -255.1° (c = 0.5 in CHCl3) | | density | 1.015±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | powder | | pka | 12.45±0.70(Predicted) | | color | white to beige | | InChIKey | YJDYDFNKCBANTM-QCWCSKBGSA-N |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | Valspodar Usage And Synthesis |
| Description | PSC 833 is a non-immunosuppressant derivative of cyclosporine and potent multidrug-resistance (MDR) modulator. It restores sensitivity of MDR-P388 murine leukemia cells to cytostatic agents when used at concentrations of 70, 33, 45, 34, and 26 nM in combination with colchicine, vincristine , daunorubicin , doxorubicin , and etoposide , respectively. PSC 833 inhibits basal-to-apical transport and increases apical-to-basal transport of [14C]docetaxel in LLC-GA5-COLO150 cells that overexpress human P-glycoprotein (P-gp). In vivo, PSC 833 increases survival time in MDR-P388 tumor-bearing mice and in an MDR-L1210 leukemia mouse xenograft model when administered in combination with doxorubicin. PSC 833 also prolongs the anti-hyperalgesic effects of intraperitoneally administered pregabalin in a mouse model of cold stress-induced central pain. | | Chemical Properties | White Solid | | Uses | Valspodar/ PSC-833 has been used as a ABCB1 (P-glycoprotein) inhibitor. | | Uses | Antineoplastic adjunct (chemosensitizer). | | Uses | Valspodar(PSC-833), a 2nd-generation ABC transporter inhibitor, limits HCMV infection as demonstrated by the decrease in IE2 expression of virus-infected cells. As a cyclosporin D analog, it has been shown to be a much more effective inhibitor of MDR than cyclosporin A and to be less toxic[1-2]. | | Definition | ChEBI: SDZ PSC 833 is a homodetic cyclic peptide. | | Brand name | Amdray (Novartis). | | Biochem/physiol Actions | Valspodar is a nonimmunosuppressive cyclosporin analog and potent P-glycoprotein (MDR1) inhibitor. Valspodar reverses multidrug resistance (MDR) by inhibiting cellular drug efflux mediated by P-glycoprotein. | | Cytotoxicity | Cells treated with increasing concentrations of valspodar over a 9-day period show minimal cytotoxicity. It appears to be neither immunosuppressive nor nephrotoxic with the ability to achieve levels in the blood (1 μm) capable of reversing drug resistance without excessive toxicity[1]. | | storage | Store at -20°C | | References | [1] Friedenberg W, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95). Cancer, 2006; 106: 830-838.
[2] Parsons J, et al. Valspodar limits human cytomegalovirus infection and dissemination. Antiviral Research, 2021; 193: 105124. |
| | Valspodar Preparation Products And Raw materials |
|